Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Endocrine therapy (ET) is integral to the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). Aromatase inhibitors (AIs; e.g., anastrozole, letrozole, exemestane), selective estrogen receptor modulators (e.g., tamoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagaraj, Gayathri, Ma, Cynthia X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854469/
https://www.ncbi.nlm.nih.gov/pubmed/33190190
http://dx.doi.org/10.1007/s12325-020-01552-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854469/
https://www.ncbi.nlm.nih.gov/pubmed/33190190
http://dx.doi.org/10.1007/s12325-020-01552-2

Ejemplares similares